Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis

N Pernigoni, E Zagato, A Calcinotto, M Troiani… - Science, 2021 - science.org
The microbiota comprises the microorganisms that live in close contact with the host, with
mutual benefit for both counterparts. The contribution of the gut microbiota to the emergence …

Second-line hormonal therapy for men with chemotherapy-naive, castration-resistant prostate cancer: American Society of Clinical Oncology Provisional Clinical …

KS Virgo, E Basch, DA Loblaw, TK Oliver… - Journal of Clinical …, 2017 - ascopubs.org
Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership
after publication or presentation of potential practice-changing data. This PCO addresses …

Molecular heterogeneity in prostate cancer and the role of targeted therapy

S Khan, P Baligar, C Tandon, J Nayyar, S Tandon - Life Sciences, 2024 - Elsevier
Data collected from large-scale studies has shown that the incidence of prostate cancer
globally is on the rise, which could be attributed to an overall increase in lifespan. So, the …

[HTML][HTML] Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus …

M Shim, WJ Bang, CY Oh, YS Lee… - … and clinical urology, 2019 - synapse.koreamed.org
Purpose To investigate the changes in testosterone levels and rates of chemical castration
following androgen-deprivation therapy (ADT) with goserelin, triptorelin, and leuprolide …

An update on triptorelin: current thinking on androgen deprivation therapy for prostate cancer

AS Merseburger, MC Hupe - Advances in therapy, 2016 - Springer
Androgen deprivation therapy (ADT) is the mainstay palliative treatment for men with locally
advanced and metastatic prostate cancer, and aims to reduce testosterone to levels …

A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants

F Sun, IR Indran, ZW Zhang, MHE Tan, Y Li… - …, 2015 - academic.oup.com
Persistent androgen receptor (AR) signaling is the key driving force behind progression and
development of castration-resistant prostate cancer (CRPC). In many patients, AR COOH …

Testosterone suppression in the treatment of recurrent or metastatic prostate cancer—A Canadian consensus statement

L Klotz, B Shayegan, C Guillemette… - Canadian …, 2017 - pmc.ncbi.nlm.nih.gov
Testosterone suppression, achieved through orchiectomy or medically induced androgen-
deprivation therapy (ADT), is a standard treatment for men with recurrent and metastatic …

Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl

ED Crawford, JW Moul, O Sartor… - Expert opinion on drug …, 2015 - Taylor & Francis
Introduction: Luteinizing hormone-releasing hormone agonists such as leuprolide acetate
(LA) are the most frequently utilized treatment of advanced prostate cancer as the regimen …

Serum testosterone levels in prostate cancer patients undergoing luteinizing hormone-releasing hormone agonist therapy

J Morote, I Comas, J Planas, X Maldonado… - Clinical Genitourinary …, 2018 - Elsevier
Background Serum testosterone measurement is recommended to assess the efficacy of
androgen deprivation therapy (ADT) and to diagnose castration resistance in patients with …

[HTML][HTML] Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer

L Klotz, RH Breau, LL Collins, ME Gleave… - Canadian Urological …, 2017 - ncbi.nlm.nih.gov
Methods: PubMed and conference proceedings were searched for studies assessing the
impact of low testosterone on clinical outcomes from ADT. The key search terms included …